FDA's Controversial Pregnancy Drug Decision, Explained

This episode is brought to you by Semafor Healthcare.Delivered weekly from David Lim, Semafor Healthcare connects the dots between decisions in government, business, and technology to reveal how they impact the future of healthcare. Each edition will provide the analysis you need to understand and stay ahead of a rapidly changing landscape. Subscribe for free.Health Affairs' Leslie Erdelack and Jessica Bylander discuss the FDA's efforts to pull the pregnancy drug Makena from the market and the implications for drug policy.Join us in D.C. for an in-person happy hour event on November 17Related Links:FDA Panel Recommends Pulling Preterm Birth Drug From the Market (New York Times)Accelerated Approval of Cancer Drugs: No Economic Reward For Drug Makers That Conduct Confirmatory Trials (Health Affairs)Delays in Confirmatory Trials for Drug Applications Granted FDA's Accelerated Approval Raise Concerns (Office of Inspector General)Podcast: Prescription Drug Policy, Drug Pricing & Aduhelm With Rachel Sachs (Health Affairs This Week)Currently, more than 70 percent of our content is freely available — and we’d like to keep it that way. With your support, we can continue to keep our digital publication Forefront and podcasts free for everyone.Subscribe: RSS | Apple Podcasts | Spotify | Castro | Stitcher | Deezer | OvercastJoin us in D.C. for an in-person happy hour event on November 17 Subscribe to Semafor Healthcare for free.